pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
785
stories
16d
Alethio raises $90M to target rare blood cancers
biopharma dive
16d
Cash-strapped Vivoryon regains China rights to kidney disease prospect from Simcere
fiercebiotech
16d
Boehringer bets big on China, offering $7B biobucks for Sino cancer programs
biospace
16d
Boehringer Ingelheim strikes $7B backloaded ADC, TCE cancer deal with China's Sino
endpoints
17d
Minghui grants ASKA Japanese rights to sub-q TED candidate in $440M deal
fiercebiotech
17d
Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs
fiercebiotech
17d
Ultragenyx shrinks workforce and axes assets to halve R&D spend
fiercebiotech
17d
6 potential blockbusters that could pave China’s path to 2030 ambitions
biospace
17d
Novo’s CEO still looking for deals to ‘close some of the gaps,’ as misfires hit profits
fiercebiotech
17d
Vertex, ahead of FDA decision, calms fears surrounding kidney drug
biopharma dive
17d
Lonza agrees to buy 5 Merck KGaA facilities to accelerate US expansion
biospace
17d
T-Therapeutics raises $133M series B for bispecific pipeline with Big Pharma backers in tow
fiercebiotech
17d
Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance
biospace
17d
Pfizer flat in Q3 despite 32% growth for new and acquired products
biospace
18d
AbbVie abandons phase 2 solid tumor drug over ‘limited benefit’
fiercebiotech
18d
BioArctic left out in the cold as Novartis walks away from $800M neuro collab
fiercebiotech
18d
Tiziana touts multiple sclerosis win at lower dose as high dose misses mark
biospace
18d
Significant stock movers of October: Biohaven climbs, ArriVent dives
biospace
19d
Teva ends trial of one of its original line-up of innovative meds over futility
fiercebiotech
19d
Lower dose of Tiziana's MS drug reduces neuroinflammation, while higher dose struggles
fiercebiotech
19d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
21d
This week in charts: ESMO’s winners and losers
biopharma dive
21d
AstraZeneca employs $1.5B cost savings to reinvest back into growth
biospace
21d
Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%
biospace
22d
Bambusa shoots past IPO targets as Aspen trims offering
fiercebiotech
22d
Platelet Factor 4 (PF4) Radioimmunoassay Recall: Instrumentation Laboratories Removes HemosIL AcuStar HIT-IgG(PF4-H)
fda medwatch
22d
Roche launches differential diagnosis test for mesothelioma
fiercebiotech
22d
Molecular Partners to lay off up to 44% of workforce in radiotherapy pivot
fiercebiotech
22d
Dren Bio lands $350M to push rare blood cancer therapy toward market
biospace
22d
R&D chief Dean Li says Merck outflanked rivals with its sac-TMT cancer program
endpoints
← prev
page 4 of 27
next →